Vera Therapeutics, Inc. granted inducement awards to six new employees, consisting of stock options and restricted stock units. The stock options have an exercise price of $24.35 per share and will vest over four years. The RSU awards will also vest over four years, with 25% vesting on each anniversary of November 20, 2025. Vera Therapeutics is a biotechnology company focused on developing treatments for immunological diseases, with a lead product candidate called atacicept. The company also holds an exclusive license for a novel fusion protein targeting BAFF and APRIL, known as VT-109.
For more information, contact Investor Contact Joyce Allaire at LifeSci Advisors or Media Contact Debra Charlesworth at Vera Therapeutics.

Read more at GlobeNewswire: Vera Therapeutics Announces Inducement Grants Under Nasdaq